Substituted phenanthrene imidazoles as potent, selective, and orally active mPGES-1 inhibitors
Bernard Côté(Merck Canada Inc. (Canada)), Louise Boulet(Merck Canada Inc. (Canada)), Christine Brideau(Merck Canada Inc. (Canada)), David Claveau(Merck Canada Inc. (Canada)), Diane Ethier(Merck Canada Inc. (Canada)), Richard Frenette(Merck Canada Inc. (Canada)), Marc Gagnon(Merck Canada Inc. (Canada)), André Giroux(Merck Canada Inc. (Canada)), Jocelyne Guay(Merck Canada Inc. (Canada)), Sébastien Guiral(Merck Canada Inc. (Canada)), Joseph A. Mancini(Merck Canada Inc. (Canada)), Evelyn Martins(Merck Canada Inc. (Canada)), Frédéric Massé(Merck Canada Inc. (Canada)), Nathalie Méthot(Merck Canada Inc. (Canada)), Denis Riendeau(Merck Canada Inc. (Canada)), Joel Rubin(Merck Canada Inc. (Canada)), Daigen Xu(Merck Canada Inc. (Canada)), Hongping Yu(Merck Canada Inc. (Canada)), Yves Ducharme(Merck Canada Inc. (Canada)), Richard W. Friesen(Merck Canada Inc. (Canada))
Cited by 128Open Access
Abstract
Related Papers
No related papers found
Powered by citation graph analysis